Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Vildagliptin
Drug: Sitagliptin
Drug: Metformin
Drug: Placebo

First Posted Date: 2009-03-12

Last Posted Date: 2020-12-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1988

Registration Number: NCT00860288

Locations: 🇰🇷
Ajou university hospital, Suwon, Korea, Republic of
🇱🇻
Daugavpils Regional Hospital, Daugavpils, Latvia
🇱🇻
Talsi Clinical Hospital, Talsi, Latvia

and more 180 locations

The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration

Phase 2

Terminated

Conditions: Choroidal Neo-Vascular Age-onset Macular Degeneration
Age-related Macular Degeneration

Interventions: Drug: Everolimus
Drug: Ranibizumab

First Posted Date: 2009-03-06

Last Posted Date: 2011-08-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 16

Registration Number: NCT00857259

Locations: 🇬🇧
Novartis Investigative Site, Southampton, United Kingdom
🇺🇸
Retina-Vitreous Associates Medical Group, Beverley Hills, California, United States
🇺🇸
Discover Vision Center, Independence, Missouri, United States

and more 4 locations

Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients

Phase 3

Completed

Conditions: Coronary Artery Disease (CAD)
Coronary Atherosclerosis

Interventions: Drug: Placebo
Drug: Aliskiren

First Posted Date: 2009-03-02

Last Posted Date: 2014-06-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 613

Registration Number: NCT00853827

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain

Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure

Phase 3

Completed

Conditions: Chronic Heart Failure

Interventions: Drug: Enalapril
Drug: Aliskiren

First Posted Date: 2009-03-02

Last Posted Date: 2016-11-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 7064

Registration Number: NCT00853658

Locations: 🇻🇪
Novartis Investigative Site, Maracaibo, Estado Zulia, Venezuela

Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension

Phase 1

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: RKI983A
Drug: Latanoprost

First Posted Date: 2009-02-19

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 276

Registration Number: NCT00846989

Locations: 🇺🇸
Novartis Investigative Site, Spokane, Washington, United States

Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS

Phase 2

Terminated

Conditions: Cryptococcal Meningitis

Interventions: Biological: placebo
Biological: Efungumab (Mycograb)
Biological: Amphotericin B
Biological: 5 flucytosine

First Posted Date: 2009-02-19

Last Posted Date: 2009-02-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 38

Registration Number: NCT00847678

Locations: 🇿🇦
Novartis Investigative Site, South Africa, South Africa

Exacerbation Study

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Indacaterol 150 µg
Drug: Tiotropium

First Posted Date: 2009-02-18

Last Posted Date: 2013-11-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3439

Registration Number: NCT00845728

Locations: 🇻🇪
Novartis Investigative Site, Maracaibo, Estado Zulia, Venezuela

Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food

Phase 4

Completed

Conditions: Transfusional Hemosiderosis

First Posted Date: 2009-02-18

Last Posted Date: 2021-07-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 65

Registration Number: NCT00845871

Locations: 🇺🇸
Children's Hospital and Research Center, Oakland, California, United States
🇺🇸
Schneider Children's Hospital, New Hyde Park, New York, United States
🇺🇸
University of Colorado Denver, Colorado Sickle Cell Treatment and Research Center, Aurora, Colorado, United States

and more 20 locations

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Indacaterol 150 μg
Drug: Tiotropium 18 μg
Drug: Placebo to indacaterol

First Posted Date: 2009-02-18

Last Posted Date: 2011-08-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1134

Registration Number: NCT00846586

Locations: 🇺🇸
Novartis Investigative site, Omaha, Nebraska, United States
🇦🇷
Novartis Investigative SIte, Mendoza, Argentina
🇪🇸
Novartis Investigative Site, Jaén, Spain

and more 2 locations

Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma

Phase 1

Terminated

Conditions: Hepatocellular Carcinoma

Interventions: Drug: RAD001
Drug: RAD001, sorafenib

First Posted Date: 2009-01-26

Last Posted Date: 2013-04-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 130

Registration Number: NCT00828594

Locations: 🇪🇸
Novartis Invstigative Site, Madrid, Spain
🇨🇳
Novartis Investigative Site, Tainan, Taiwan
🇺🇸
City of Hope Medical Center, Duarte, California, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy